Folate-Dependent Hydrolysis of Acetyl-Coenzyme A by Recombinant Human and Rodent Arylamine N-Acetyltransferases

Overview

Journal Biochem Biophys Rep

Specialty Biochemistry

Date 2015 Aug 27

PMID 26309907

Citations 18

Authors

Marcus W Stepp

Galina Mamaliga

Mark A Doll

J Christopher States

David W Hein

Affiliations

Soon will be listed here.

Abstract

Arylamine -acetyltransferases (NATs) are drug and xenobiotic metabolizing enzymes that catalyze the N-acetylation of arylamines and hydrazines and the O-acetylation of N-hydroxy-arylamines. Recently, studies report that human NAT1 and mouse Nat2 hydrolyze acetyl-coenzyme A (AcCoA) into acetate and coenzyme A in a folate-dependent fashion, a previously unknown function. In this study, our goal was to confirm these findings and determine the apparent Michaelis-Menten kinetic constants (Vmax and Km) of the folate-dependent AcCoA hydrolysis for human NAT1/NAT2, and the rodent analogs rat Nat1/Nat2, mouse Nat1/Nat2, and hamster Nat1/Nat2. We also compared apparent Vmax values for AcCoA hydrolysis and N-acetylation of the substrate para-aminobenzoic acid (PABA). Human NAT1 and its rodent analogs rat Nat2, mouse Nat2 and hamster Nat2 catalyzed AcCoA hydrolysis in a folate-dependent manner. Rates of AcCoA hydrolysis were between 0.25 - 1% of the rates for N-acetylation of PABA catalyzed by human NAT1 and its rodent orthologs. In contrast to human NAT1, human NAT2 and its rodent analogs rat Nat1, mouse Nat1, and hamster Nat1 did not hydrolyze AcCoA in a folate-dependent manner. These results are consistent with the possibility that human NAT1 and its rodent analogs regulate endogenous AcCoA levels.

Citing Articles

CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics.

Tiwari P, Ko T, Dubey R, Chouhan M, Tsai L, Singh H Front Mol Biosci. 2023; 10:1214489.

PMID: 37469704 PMC: 10352522. DOI: 10.3389/fmolb.2023.1214489.

Acetyl coenzyme A kinetic studies on -acetylation of environmental carcinogens by human -acetyltransferase 1 and its variant.

Habil M, Doll M, Hein D Front Pharmacol. 2022; 13:931323.

PMID: 36386142 PMC: 9650386. DOI: 10.3389/fphar.2022.931323.

Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells.

Hong K, Tagnedji A, Doll M, Walls K, Hein D J Cancer Res Clin Oncol. 2022; 149(8):5047-5060.

PMID: 36329350 PMC: 10193532. DOI: 10.1007/s00432-022-04436-w.

Transcriptional Regulation of Human Arylamine N-Acetyltransferase 2 Gene by Glucose and Insulin in Liver Cancer Cell Lines.

Hong K, Salazar-Gonzalez R, Walls K, Hein D Toxicol Sci. 2022; 190(2):158-172.

PMID: 36156098 PMC: 9702998. DOI: 10.1093/toxsci/kfac103.

Human -Acetyltransferase 1 and 2 Differ in Affinity Towards Acetyl-Coenzyme A Cofactor and -Hydroxy-Arylamine Carcinogens.

Hein D, Doll M, Habil M Front Pharmacol. 2022; 13:821133.

PMID: 35281898 PMC: 8914035. DOI: 10.3389/fphar.2022.821133.

References

Laurieri N, Dairou J, Egleton J, Stanley L, Russell A, Dupret J . From arylamine N-acetyltransferase to folate-dependent acetyl CoA hydrolase: impact of folic acid on the activity of (HUMAN)NAT1 and its homologue (MOUSE)NAT2. PLoS One. 2014; 9(5):e96370. PMC: 4019507. DOI: 10.1371/journal.pone.0096370. View

Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O . Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat. 2008; 114(1):47-62. DOI: 10.1007/s10549-008-9982-8. View

Hein D . Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002; 506-507:65-77. DOI: 10.1016/s0027-5107(02)00153-7. View

Doll M, Hein D . Cloning, sequencing and expression of NAT1 and NAT2 encoding genes from rapid and slow acetylator inbred rats. Pharmacogenetics. 1995; 5(4):247-51. DOI: 10.1097/00008571-199508000-00009. View

Tiang J, Butcher N, Cullinane C, Humbert P, Minchin R . RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One. 2011; 6(2):e17031. PMC: 3036737. DOI: 10.1371/journal.pone.0017031. View

Sim E, Lack N, Wang C, Long H, Westwood I, Fullam E . Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology. 2008; 254(3):170-83. DOI: 10.1016/j.tox.2008.08.022. View

Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adelaide J . Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene. 2004; 23(14):2564-75. DOI: 10.1038/sj.onc.1207361. View

Deghan Manshadi S, Ishiguro L, Sohn K, Medline A, Renlund R, Croxford R . Folic acid supplementation promotes mammary tumor progression in a rat model. PLoS One. 2014; 9(1):e84635. PMC: 3897399. DOI: 10.1371/journal.pone.0084635. View

Llanos A, Dumitrescu R, Brasky T, Liu Z, Mason J, Marian C . Relationships among folate, alcohol consumption, gene variants in one-carbon metabolism and p16INK4a methylation and expression in healthy breast tissues. Carcinogenesis. 2014; 36(1):60-7. PMC: 4351383. DOI: 10.1093/carcin/bgu219. View

10.

Weigelt B, Glas A, Wessels L, Witteveen A, Peterse J, Vant Veer L . Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A. 2003; 100(26):15901-5. PMC: 307665. DOI: 10.1073/pnas.2634067100. View

11.

Abba M, Hu Y, Sun H, Drake J, Gaddis S, Baggerly K . Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics. 2005; 6:37. PMC: 555753. DOI: 10.1186/1471-2164-6-37. View

12.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

13.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

14.

Wakefield L, Cornish V, Long H, Kawamura A, Zhang X, Hein D . Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system. Biomarkers. 2007; 13(1):106-18. PMC: 2430772. DOI: 10.1080/13547500701673529. View

15.

Walraven J, Doll M, Hein D . Identification and characterization of functional rat arylamine N-acetyltransferase 3: comparisons with rat arylamine N-acetyltransferases 1 and 2. J Pharmacol Exp Ther. 2006; 319(1):369-75. DOI: 10.1124/jpet.106.108399. View

16.

Fretland A, Doll M, Leff M, Hein D . Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics. 2001; 11(6):511-20. DOI: 10.1097/00008571-200108000-00006. View

17.

Adam P, Berry J, Loader J, Tyson K, Craggs G, Smith P . Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res. 2003; 1(11):826-35. View

18.

Hein D, Boukouvala S, Grant D, Minchin R, Sim E . Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics. 2008; 18(4):367-8. PMC: 2386960. DOI: 10.1097/FPC.0b013e3282f60db0. View

19.

Goodfellow G, Dupret J, Grant D . Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J. 2000; 348 Pt 1:159-66. PMC: 1221049. View

20.

Hein D, Doll M, Fretland A, Leff M, Webb S, Xiao G . Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000; 9(1):29-42. View